>
SPLC 'Fascism Expert' Funneled $1.2 MILLION in Donor Cash to Her Neo-Nazi Informant/Lover
Israeli Ministers Say Israel Isn't Bound by US-Iran Deal, Won't Withdraw From Lebanon
EXCLUSIVE: Top FBI Whistleblower Says The Supposed Terror Plot Targeting The White House...
Heads up: Apparently the government is hiding cameras inside fake utility boxes
Sodium Batteries And EVs That Power The Grid: Inside GM's Big Energy Push
NUCLEAR ENGINE - UNLIMITED LUXURY - 20 YEARS WITHOUT REFUELING
China Unveils Nuclear-Powered Floating Hub For Green Shipping
China Launches World's 1st Commercial Brain Chip, Beating Elon Musk's Neuralink!
Modular next-gen US nuclear reactor goes critical
This Company Will Add Phone, AirPod, and Smartwatch Trackers to License Plate Readers
Elon Details SpaceX AI Data Center in Space Details and Roadmap

Above- Three essential tools for human gene therapy. AAV and lentiviral vectors are the basis of several recently approved gene therapies. Gene editing technologies are in their translational and clinical infancy but are expected to play an increasing role in the field.
BACKGROUND
Nearly five decades ago, visionary scientists hypothesized that genetic modification by exogenous DNA might be an effective treatment for inherited human diseases. This "gene therapy" strategy offered the theoretical advantage that a durable and possibly curative clinical benefit would be achieved by a single treatment. Although the journey from concept to clinical application has been long and tortuous, gene therapy is now bringing new treatment options to multiple fields of medicine. We review critical discoveries leading to the development of successful gene therapies, focusing on direct in vivo administration of viral vectors, adoptive transfer of genetically engineered T cells or hematopoietic stem cells, and emerging genome editing technologies.